Towards next generation maggot debridement therapy: transgenic Lucilia sericata larvae that produce and secrete a human growth factor

Volume: 16, Issue: 1
Published: Mar 22, 2016
Abstract
Diabetes and its concurrent complications impact a significant proportion of the population of the US and create a large financial burden on the American health care system. FDA-approved maggot debridement therapy (MDT), the application of sterile laboratory-reared Lucilia sericata (green bottle fly) larvae to wounds, is a cost-effective and successful treatment for diabetic foot ulcers and other medical conditions. Human platelet derived growth...
Paper Details
Title
Towards next generation maggot debridement therapy: transgenic Lucilia sericata larvae that produce and secrete a human growth factor
Published Date
Mar 22, 2016
Volume
16
Issue
1
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.